* Praxis Precision Medicines Inc PRAX.OQ reported a
quarterly
adjusted loss of $1.74 per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-7.35. The mean expectation of ten analysts
for the quarter was for a loss of $2.31 per share. Wall Street
expected results to range from $-3.24 to $-1.72 per share.
* Revenue fell 54.3% to $357.00 thousand from a year ago;
analysts
expected $833.00 thousand.
* Praxis Precision Medicines Inc's reported EPS for the
quarter
was a loss of $1.74.
* The company reported a quarterly loss of $32.68 million.
* Praxis Precision Medicines Inc shares had risen by 25.3%
this
quarter and gained 132.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Praxis Precision
Medicines Inc is $143.00
This summary was machine generated from LSEG data August 13 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -2.31 -1.74 Beat
Mar. 31 2024 -2.08 -2.84 Missed
Dec. 31 2023 -3.18 -2.97 Beat
Sep. 30 2023 -5.25 -2.70 Beat